Drawing for TERAVENA

USPTO serial 99572163

TERAVENA

Reviewed by CopyMark Law Group

Status 774
Filing date
Status date
Registration date
—
Examiner
DANG, BAO-NGOC K
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TERAVENA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Nutritional supplements for promoting healthACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 26, 2026OP.IOPPOSITION INSTITUTED NO. 999999—
Jun 26, 2026OPPFOPPOSITION PAPERS RECEIVED AT TTAB—
Jun 2, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 2, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 27, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 1, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 1, 2026LOPRLETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN—
Apr 29, 2026DOCKASSIGNED TO EXAMINER—
Apr 24, 2026LOPTLETTER OF PROTEST EVIDENCE FORWARDED—
Apr 10, 2026WOAGWITHDRAWAL OF ATTORNEY GRANTED—
Apr 10, 2026WOARTEAS WITHDRAWAL OF ATTORNEY RECEIVED—
Dec 30, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 30, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 30, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance